163 related articles for article (PubMed ID: 31543370)
21. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
Mitsunobu T; Nishikawa T; Kusuda M; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e456-e458. PubMed ID: 31274669
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
23. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
24. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
[No Abstract] [Full Text] [Related]
25. Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.
Ohya K; Okuyama S; Ogata SY; Maeda K; Yamada K; Ohshima K; Tajima K
Ann Hematol; 2021 Nov; 100(11):2873-2875. PubMed ID: 34427738
[No Abstract] [Full Text] [Related]
26. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
27. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
28. Promising new second-line therapy for Hodgkin lymphoma.
Gourd E
Lancet Oncol; 2019 Feb; 20(2):e76. PubMed ID: 30686705
[No Abstract] [Full Text] [Related]
29. Transformation of Grade I Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD30+ ALK1- with Complete Response to Brentuximab Vedotin and High-Dose Methotrexate.
Al-Mansour M; Al-Maghraby H; Shirah B
Gulf J Oncolog; 2020 May; 1(33):87-90. PubMed ID: 32476657
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
Vonasek J; Edslev PW; d'Amore F; Hasle H
Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
[No Abstract] [Full Text] [Related]
32. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
Choi Y; Diefenbach CS
Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
[No Abstract] [Full Text] [Related]
33. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
[No Abstract] [Full Text] [Related]
34. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
35. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
37. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.
Belia M; Chatzidimitriou C; Rondogianni P; Petsa P; Efstathopoulou M; Konstantinou E; Arapaki M; Asimakopoulos J; Plata E; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP
Hematol Oncol; 2021 Apr; 39(2):258-262. PubMed ID: 32905619
[No Abstract] [Full Text] [Related]
38. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
39.
Wang M; Kibbi N; Ring N; Siddon A; Foss F; Totonchy M
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570354
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
